Technology for the Future

Every morning, the YouTube program 'Startup Morning Coffee,' which opens the vibrant door to the startup ecosystem, greets viewers with CEO Jeon Hwa-sung as its host. Broadcast live from 8:40 AM on the 'Jeon Hwa-sung's CNTV' channel, this program deeply illuminates the core competencies and market potential of promising startups, establishing itself as a platform that provides valuable insights to viewers through real-time communication. The innovative company recently spotlighted by 'Startup Morning Coffee' is Bidymass. Bidymass, which features malaria rapid diagnostic kits as its main product, is bringing an innovative wave to the field of antibody production. In particular, by developing MCCS (Membrane Cell Culture System), a proprietary antibody production solution that does not use animals, it is presenting a sustainable future for the biotech industry. MCCS, which directly cultures hybridoma cells within a membrane, has the advantage of being not only more eco-friendly than existing methods but also overwhelmingly superior in production efficiency. Currently, Bidymass is accelerating its technological advancement with support from CNTTech's Gangwon K-Camp. The core of Bidymass's MCCS technology lies in its 'innovative value' that transcends mere efficiency. This system has achieved a remarkable 30-fold increase in production volume compared to conventional cell culture methods, improved performance for specific reactions by 35%, and at the same time, accomplished the feat of reducing overall unit costs by approximately 30%. When compared to alternative technologies based on animal testing or utilizing recombinant antibodies, this clearly demonstrates Bidymass's unparalleled competitiveness. Based on this powerful technology, Bidymass plans to supply antibodies to demand companies through a B2B model, initially targeting the malaria rapid diagnostic kit market. CEO Jeon Hwa-sung emphasized Bidymass's future, stating, "We expect full-scale revenue generation starting next year and are actively pursuing global expansion strategies, including entering the vitamin D diagnostic antibody market and targeting the Indonesian market." A strong team composed of expert researchers in the fields of iris and tobacco processing adds to Bidymass's technical depth. Through its eco-friendly and highly efficient antibody production technology, Bidymass is expected to contribute to the sustainable development of the biotech industry and, furthermore, become a leader in the global market.